Clinical trials are being conducted to evaluate the effectiveness of different treatments for colorectal and esophagogastric adenocarcinoma, including trifluridine/tipiracil with or without oxaliplatin, and riluzole for preventing oxaliplatin-induced peripheral neuropathy.